Table 1 Description of the IME characteristics before and after neoadjuvant chemotherapy in the entire population (comparison with paired-test)
| Â | Â | Before chemo (n = 66) N (%) | After chemo (n = 66) N (%) | Â |
|---|---|---|---|---|
TILs (%) | Median | 10.0 | 10.0 | p = 0.5598 |
(Range) | (1.0:95.0) | (1.0:70.0) | ||
TILs | 0–10% | 36 (54.5%) | 35 (53.0%) | p = 0.8474 |
> 10% | 30 (45.5%) | 31 (47.0%) | ||
TILs | 0–30% | 56 (84.8%) | 58 (87.9%) | p = 0.5930 |
> 30% | 10 (15.2%) | 8 (12.1%) | ||
PD-L1 | Negative (IC0) | 31 (47.0%) | 38 (57.6%) | p = 0.1936 |
Positive (IC1/2/3) | 35 (53.0%) | 28 (42.4%) | ||
TIM-3 (%) | Median | 0.0 | 1.5 | p < 0.0001 |
(Range) | (0.0:15.0) | (0.0:20.0) | ||
TIM-3 | < 1% | 45 (68.2%) | 21 (31.8%) | p < 0.0001 |
≥1% | 21 (31.8%) | 45 (68.2%) | ||
TIM-3 | 0–4% | 57 (86.4%) | 44 (66.7%) | p = 0.0093 |
≥5% | 9 (13.6%) | 22 (33.3%) | ||
PD-L1 and TIM-3 | Others | 62 (93.9%) | 54 (81.8%) | p = 0.0209 |
PD-L1+/TIM-3+ | 4 (6.1%) | 12 (18.2%) | ||
LAG-3 (%) | Median | 2.5 | 3.0 | p = 0.0389 |
(Range) | (0.0:37.0) | (0.0:23.0) | ||
LAG-3 | 0 | 15 (22.7%) | 11 (16.7%) | p = 0.3173 |
> 0 | 51 (77.3%) | 55 (83.3%) | ||
LAG-3 | 0–9 | 49 (74.2%) | 58 (87.9%) | p = 0.0126 |
≥10 | 17 (25.8%) | 8 (12.1%) |